Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

PURPOSE: The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Disis, Mary L., Wallace, Danelle R., Gooley, Theodore A., Dang, Yushe, Slota, Meredith, Lu, Hailing, Coveler, Andrew L., Childs, Jennifer S., Higgins, Doreen M., Fintak, Patricia A., dela Rosa, Corazon, Tietje, Kathleen, Link, John, Waisman, James, Salazar, Lupe G.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2009
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754913/
https://ncbi.nlm.nih.gov/pubmed/19720923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.6789
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge